Laurus Labs Ltd

Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 874.75, up 1.7% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.15% on the day, quoting at 24615.6. The Sensex is at 80252.95, up 0.12%. Laurus Labs Ltd has risen around 1.57% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 1.03% in last one month and is currently quoting at 21719.95, up 0.94% on the day. The volume in the stock stood at 7.54 lakh shares today, compared to the daily average of 15.93 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 876.65, up 1.29% on the day. Laurus Labs Ltd is up 83.93% in last one year as compared to a 2.31% drop in NIFTY and a 5.43% drop in the Nifty Pharma index.The PE of the stock is 91.1 based on TTM earnings ending June 25.Powered by Capital Market - Live

Gross margin improved to 59.4% in Q1 June 2025, up from 55.1% in Q1 June 2024. Profit before tax (PBT) stood at Rs 224 crore for Q1 June 2025, reflecting a 1,144% increase over Q1 June 2024. EBITDA was Rs 389 crore in Q1 June 2025, up 127% compared to Q1 June 2024. EBITDA margin rose to 24.8%, up from 14.3% in Q1 June 2024. In Q1 FY26, Laurus Labs' Contract Development and Manufacturing Operations (CDMO) revenue more than doubled year-on-year to Rs 522 crore, driven by a 130% increase in small molecules revenue, although the bio-segment saw a 33% decline. Revenue from the Generics division rose 12% to Rs 1,048 crore, with APIs dipping 4% but finished dosages (FDF) surging 50%. Additionally, ARV revenues advanced 17% to Rs 647 crore during the period under review. Dr. Satyanarayana Chava, founder & chief executive officer commented: We made healthy progress to start the year with increasing contributions from CDMO business and continued advancement of pipeline projects, supported by Generic FDF. We are moving ahead with strong focus on commercial execution realizing the full potential from promising pipeline opportunities, business development and rapidly enhancing scale and technology capabilities. We also commenced construction of various facilities across CDMO, Generics and FDF. Once complete, these facilities will fortify our ongoing commitment of being a high-quality development and manufacturing partner at scale including advanced therapies. We remain confident in our strategic direction and commitment as the source of sustainable value creation now and well into the future. V V Ravi Kumar, executive director & chief financial officer commented: We delivered a solid performance in Q1, in line with expectations. We are pleased to see sustained growth momentum fueled by increasing uptake in CDMO deliveries and healthy business fundamentals. The EBITDA margins improved substantially to 24.8%, supported by continuing operating leverage. Gross margins stood strong at 59.4% due to favorable CDMO mix and ongoing process improvement initiatives. We will continue to invest fully behind high value business opportunities to drive near and long-term growth and returns for our shareholders. Meanwhile, the Government of Andhra Pradesh has allotted 531.77 acres of land in IP Rambilli Phase-II, Anakapalli District, to the company for the establishment of Laurus Pharma Zone (LPZ), where it plans to set up manufacturing units for pharmaceutical products. Laurus Labs has earmarked an investment of Rs 5,630 crore for this project, which is expected to generate employment for 6,350 people in three phases over eight years. This land allotment marks a significant milestone, securing a crucial component for the company's future expansion plans. Laurus Labs is a research-driven pharmaceutical and biotechnology company. It develops and manufactures select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. It offers end-to-end CDMO services, supporting innovators from early-stage development to commercial production. Powered by Capital Market - Live

Laurus Labs Ltd gained for a third straight session today. The stock is quoting at Rs 893.5, up 6.65% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 24744.75. The Sensex is at 81052.89, down 0.5%. Laurus Labs Ltd has risen around 23.27% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 3.26% in last one month and is currently quoting at 22662.7, up 0.42% on the day. The volume in the stock stood at 132.02 lakh shares today, compared to the daily average of 25.38 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 894.85, up 6.89% on the day. Laurus Labs Ltd is up 98.12% in last one year as compared to a 0.37% drop in NIFTY and a 4.99% drop in the Nifty Pharma index.The PE of the stock is 133.02 based on TTM earnings ending March 25.Powered by Capital Market - Live

Poonawalla Fincorp Ltd, Kajaria Ceramics Ltd, Aadhar Housing Finance Ltd, SBI Life Insurance Company Ltd are among the other stocks to see a surge in volumes on BSE today, 28 July 2025.Laurus Labs Ltd registered volume of 5.58 lakh shares by 10:46 IST on BSE, a 6.88 fold spurt over two-week average daily volume of 81093 shares. The stock rose 5.78% to Rs.886.45. Volumes stood at 1.44 lakh shares in the last session.Poonawalla Fincorp Ltd saw volume of 3.01 lakh shares by 10:46 IST on BSE, a 5.05 fold spurt over two-week average daily volume of 59535 shares. The stock increased 6.24% to Rs.439.30. Volumes stood at 1.15 lakh shares in the last session.Kajaria Ceramics Ltd witnessed volume of 12.48 lakh shares by 10:46 IST on BSE, a 4.66 times surge over two-week average daily volume of 2.68 lakh shares. The stock increased 1.05% to Rs.1,179.70. Volumes stood at 4.16 lakh shares in the last session.Aadhar Housing Finance Ltd registered volume of 4.11 lakh shares by 10:46 IST on BSE, a 4.19 fold spurt over two-week average daily volume of 98011 shares. The stock rose 4.53% to Rs.519.40. Volumes stood at 56797 shares in the last session.SBI Life Insurance Company Ltd recorded volume of 72077 shares by 10:46 IST on BSE, a 3.28 times surge over two-week average daily volume of 21965 shares. The stock gained 0.67% to Rs.1,845.15. Volumes stood at 64706 shares in the last session.Powered by Capital Market - Live

Net profit of Laurus Labs rose 1203.12% to Rs 163.02 crore in the quarter ended June 2025 as against Rs 12.51 crore during the previous quarter ended June 2024. Sales rose 31.35% to Rs 1569.57 crore in the quarter ended June 2025 as against Rs 1194.91 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1569.571194.91 31 OPM %24.3514.33 - PBDT341.06124.52 174 PBT224.2218.46 1115 NP163.0212.51 1203 Powered by Capital Market - Live

Laurus Labs will hold a meeting of the Board of Directors of the Company on 25 July 2025.Powered by Capital Market - Live

Laurus Labs has invested Rs 39.99 crore and acquired 15,414 Series A2 Compulsorily Convertible Preference Shares of Laurus Bio, a subsidiary of the company at face value of Rs 100/- and premium of Rs 25,850.02/- each by way of Private Placement cum Preferential Allotment basis.Powered by Capital Market - Live

Laurus Labs Ltd rose for a fifth straight session today. The stock is quoting at Rs 680.9, up 1.63% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.62% on the day, quoting at 25402.2. The Sensex is at 83287.99, up 0.64%. Laurus Labs Ltd has added around 13.14% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 0.94% in last one month and is currently quoting at 21804.8, down 0.35% on the day. The volume in the stock stood at 9.15 lakh shares today, compared to the daily average of 16.82 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 678.1, up 0.97% on the day. Laurus Labs Ltd is up 60.78% in last one year as compared to a 5.65% gain in NIFTY and a 11.34% gain in the Nifty Pharma index.The PE of the stock is 106.14 based on TTM earnings ending March 25.Powered by Capital Market - Live

Laurus Labs announced that the 20th Annual General Meeting(AGM) of the company will be held on 26 June 2025.Powered by Capital Market - Live

Revenue from operations jumped 19.49% YoY to Rs 1,720.30 crore in Q4 FY25. Profit before tax (PBT) soared 191.17% to Rs 312.34 crore during the quarter ended 31st March 2025. EBITDA stood at Rs 477 crore in Q4 FY25, recording growth of 84%, as compared with Rs 259 crore in Q4 FY24. It includes one-time gain of Rs 59 crore from sale of land in 4Q FY25. EBITDA margin expanded to 27.7% in Q4 FY25 as against 18% in Q4 FY24. Revenue from CDMO segment jumped 85% to Rs 490 crore in Q4 FY25 as compared with Rs 265 crore in Q4 FY24. In Q4 FY25, revenue from small molecules jumped 95% YoY to Rs 461 crore, driven by several mid-to-late stage NCE deliveries and steady increase in sales from new manufacturing assets. While revenue from Bio business remained flat YoY at Rs 29 crore during the quarter. Revenue from generics business rose 5% to Rs 1,230 crore during the quarter as compared with Rs 1,175 crore in Q4 FY24. Revenue from API business declined 8% YoY to Rs 686 crore in Q4 FY25, while revenue from Finished Dosages Form (FDF) climbed 27% YoY to Rs 544 crore during the quarter. The company said that multiple integrated CMO contract signed, supplies started. FDF manufacturing lines expansion on track ' coming online by Dec-25. 'Continued investments in growth projects with CAPEX at 12% of Revenue to support long term growth' the company stated in exchange filing. On financial year basis, the company's consolidated net profit surged 123.18% to Rs 358.32 crore in FY25 as compared with Rs 160.55 crore in FY24. Revenue from operations jumped 10.18% to Rs 5,553.96 crore in FY25 as against Rs 5,040.83 crore in FY24, driven by robust demand environment for the company's CDMO offering and higher FDF sales. Satyanarayana Chava, founder 'Our business remains well positioned to evolve into a well-diversified CMO/CDMO company with promising pipeline, enabling several technology platforms and commercial excellence, thanks to team commitment to the unified vision of delivering high quality integrated solution and securing our long-term growth potential.' V V Ravi Kumar, executive director 'Despite the ongoing macroeconomic challenges, we have witnessed high level of demand for our offerings. For Q4, we delivered Rs 1,720 crore in revenues, growth of 19% and Rs 477 crore EBITDA grew by 84%, resulting in 27.7% margin. Gross margins remained healthy at 55% due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy. Overall FY25 results, we have delivered revenues of Rs 5,554 crore, representing 10% growth and EBITDA stood at Rs 1,115 crore, growth of 40%. The EBITDA margin of 20.1% has substantially improved, supported by continuing operating leverage within CDMO business. Going ahead, we remain confident in our growth expectations as we look forward to execute on long lead programs, new assets ramp up with revenue increasing over FY25 with continued focus on operational excellence. Our capital allocation strategy remain unchanged, prioritizing investments into high value business opportunities.' Meanwhile, the company's board approved a 2nd interim dividend of Rs 0.80 per share of Rs 2 each for FY25. The company has fixed May 09, 2025 as the record date for the said dividend. The amount will be paid on or after May 20, 2025. Laurus Labs is a research-driven pharmaceutical manufacturing organization, it has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. It has three business divisions Generics (API+FDF), CDMO (Synthesis) and Bio. The counter shed 0.51% to end at Rs 647.15 on the BSE.Powered by Capital Market - Live